NABI BIOPHARMACEUTICALS (NABI) has 45 open-market insider trades by 12 insiders since 2006. The most active filer is Jason Aryeh, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Daniel S. Loeb | — | — | 1 | $5.9M | 2007-05-10 |
| Jason Aryeh | Dir | — | 24 | $3.1M | 2011-03-15 |
| David M. Knott Jr. | 10% | — | 2 | $721K | 2009-06-30 |
| Point Offshore Fund Ltd. Third | — | — | 1 | $341K | 2006-11-03 |
| Jordan I. Siegel | Sr. VP Fin. & AdminCFO Treas | — | 2 | $249K | 2008-03-10 |
| Paul D. Kessler | CMOSVP ClinicalMed. & Reg. | — | 5 | $161K | 2012-04-05 |
| Matthew W. Kalnik | SVP Strategic Plan. & Bus. Ops | — | 2 | $127K | 2011-04-01 |
| Raafat E. F. Fahim | PresCEO and CFO | — | 3 | $123K | 2011-04-05 |
| Leslie Hudson | Dir | — | 1 | $98K | 2008-04-03 |
| Peter B. Davis | Dir | — | 2 | $35K | 2010-05-20 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Paul D. Kessler | CMO & SVP Clinical +1 | Sell | $10K | 2012-04-05 |
| Paul D. Kessler | CMO & SVP Clinical +1 | Sell | $68K | 2011-05-16 |
| Raafat E. F. Fahim | President & CEO and CFO | Sell | $77K | 2011-04-05 |
| Paul D. Kessler | CMO & SVP Clinical +1 | Sell | $50K | 2011-04-05 |
| Matthew W. Kalnik | SVP Strategic Plan. & Bus. Ops | Sell | $37K | 2011-04-01 |
| Jason Aryeh | Director | Sell | $29K |
Companies that share insiders with NABI, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2011-03-15 |
| Jason Aryeh | Director | Sell | $20K | 2011-03-14 |
| Jason Aryeh | Director | Sell | $142K | 2011-03-11 |
| Raafat E. F. Fahim | President & CEO and CFO | Sell | $18K | 2011-01-05 |
| Paul D. Kessler | CMO & SVP Clinical +1 | Sell | $17K | 2011-01-05 |
| Jason Aryeh | Director | Sell | $87K | 2010-12-27 |
| Jason Aryeh | Director | Sell | $11K | 2010-12-15 |
| Jason Aryeh | Director | Sell | $26K | 2010-12-08 |
| Jason Aryeh | Director | Sell | $37K | 2010-12-01 |
| Jason Aryeh | Director | Sell | $43K | 2010-11-18 |